A monster launch, priced for perfection
- BRINSUPRI has quickly become Insmed's largest product, with management raising its peak sales estimate to over $7 billion.
- ARIKAYCE added $98.1 million in Q1 2026 and may get a wider MAC lung disease label after positive ENCORE data.
- The company added 7,000 new BRINSUPRI patients in Q2 2026 and raised full year revenue guidance to $1.25 billion to $1.4 billion.
- The bear case is valuation, as the stock needs a clean launch, steady ARIKAYCE sales, and good TPIP data to support its price.
- TPIP peak sales expectations were increased to over $6 billion based on positive 12-month open-label extension data.
The launch changed the story
Insmed used to look like a one-product biotech waiting on a big approval. That changed after BRINSUPRI, an oral medicine for bronchiectasis, launched in the US in August 2025. In Q1 2026, BRINSUPRI revenue was $207.9 million, or 68.0% of product revenue. ARIKAYCE, the older inhaled antibiotic for MAC lung disease, brought in $98.1 million.
The bull case is fundamentally strengthened by incredible early adoption. In Q2 2026, BRINSUPRI added about 7,000 new patients. Management raised 2026 BRINSUPRI revenue guidance to between $1.25 billion and $1.4 billion, and increased global peak sales expectations to over $7 billion. TPIP peak sales expectations also rose to over $6 billion after strong long-term data in pulmonary arterial hypertension.
ARIKAYCE also matters. Positive ENCORE trial data in March 2026 supports a planned sNDA, which is a request to the FDA to expand an approved drug's label, in the second half of 2026. If approved, ARIKAYCE could reach all MAC lung disease patients, not only its narrower current group.
The bear case centers on execution and price. Finn's valuation score is extremely low, which means the market expects flawless performance. Brensocatib failed in CRSsNP and HS, two other disease areas, meaning growth outside bronchiectasis depends heavily on TPIP and the core respiratory pipeline.
Two lung drugs pay the bills
Insmed makes money by selling prescription drugs through specialty pharmacies and distributors. Almost all current revenue comes from the Respiratory area, through BRINSUPRI and ARIKAYCE.
BRINSUPRI is the growth engine. It is a once-daily oral DPP1 inhibitor for bronchiectasis, a long-term lung disease where damaged airways lead to flare-ups and infection risk. Its edge is being first to market for that use, plus the enormous size of the untreated need.
ARIKAYCE is the established product. It is an inhaled antibiotic for MAC lung disease, a hard-to-treat lung infection. Insmed's proprietary Pulmovance liposomal delivery technology helps deliver the drug to the lungs.
The model can break in simple ways. Payers may tighten access, doctors may slow new starts, patients may stop therapy, or contract manufacturers may fail to supply enough product. Insmed also still spends heavily on research and sales, so the path to steady profit relies on keeping BRINSUPRI growth strong.
What Insmed is selling and testing
BRINSUPRI
An oral, once-daily drug for bronchiectasis. It launched in the US in Q3 2025 and management expects over $7 billion in peak sales.
ARIKAYCE
An inhaled antibiotic for adult MAC lung disease. Positive ENCORE data supports a planned US label expansion filing in the second half of 2026.
TPIP
An inhaled treprostinil prodrug being tested in pulmonary diseases. Management sees a $6 billion peak sales opportunity following positive open-label data.
INS1148
A Phase 2-ready antibody acquired in December 2025. Insmed plans to study it in interstitial lung disease and asthma.
INS1201 and INS1202 gene therapy
Early gene therapy programs targeting Duchenne muscular dystrophy and ALS. Both are in Phase 1 trials.
Stopped brensocatib expansions
Insmed stopped brensocatib work in CRSsNP and HS after failed Phase 2b studies. That narrows the growth story outside bronchiectasis.
Revenue is now BRINSUPRI-led
The mix is for the three months ended March 31, 2026. Product revenue was split between BRINSUPRI at 68.0% and ARIKAYCE at 32.0%, with the United States making up 88.3% of total revenue.
What could go wrong
BRINSUPRI launch slows down
High impact · Medium oddsNew drugs often get a massive first wave from patients who were waiting for treatment. The key question is whether BRINSUPRI can maintain its 7,000 quarterly new patient start pace organically. Any stumble would reset valuation expectations.
ARIKAYCE loses focus
Medium impact · Medium oddsThe internal thesis notes that ARIKAYCE growth could stall if the sales team and doctors shift too much attention to BRINSUPRI. The planned label expansion could offset this, but only if the filing and regulatory review go well.
TPIP data disappoints
High impact · Medium oddsWith brensocatib expansion programs failing, more weight is on TPIP. Management set a $6 billion peak sales target, which assumes successful Phase 3 outcomes and breaking existing orphan drug exclusivity. If trials are weak or delayed, the valuation gets harder to defend.
Regulators or payers push back
High impact · Medium oddsInsmed needs regulators to accept wider use of ARIKAYCE and needs payers to keep covering BRINSUPRI without tight restrictions. Insurers could add paperwork, deny claims, or force patients to try other drugs first.
Outside manufacturers stumble
Medium impact · Low oddsInsmed does not own its own manufacturing sites and relies entirely on contract manufacturers. A quality issue or supply delay could hurt both commercial sales and clinical trials.
Spending stays ahead of cash generation
Medium impact · Medium oddsInsmed has a long history of losses and still funds a massive sales force and late-stage research program. BRINSUPRI improves the cash picture, but the company may still need capital if launches cost more than expected.
In one breath
What does Insmed do?
Insmed develops and sells medicines for serious lung diseases and rare diseases. Its main products are BRINSUPRI for bronchiectasis and ARIKAYCE for MAC lung disease.
Why is BRINSUPRI important to INSM stock?
BRINSUPRI is now Insmed's biggest product by revenue, adding 7,000 new patients in Q2 2026 alone. Management expects it to generate over $7 billion in peak sales.
What is the next big catalyst for Insmed?
The next items to watch are ongoing BRINSUPRI launch metrics, the ARIKAYCE sNDA filing expected in the second half of 2026, and TPIP Phase 3 trial initiations.
Why is Finn cautious on valuation?
Insmed has massive growth potential, but the market price appears to assume near-perfect execution. The stock needs BRINSUPRI to keep exploding and TPIP to deliver.
